When was ChemoCentryx founded?

ChemoCentryx was founded in 1997 and raised its 1st funding round 7 years after it was founded.

Where is ChemoCentryx located?

ChemoCentryx is headquartered in Mountain View, United States. It is registered at 835 Industrial Rd. Suite 600 San Carlos, CA 94070.

Who is the current CEO of ChemoCentryx?

Thomas Schall of ChemoCentryx. They are also an angel investors in 1 startup.

How many employees does ChemoCentryx have?

As of Sep 30, 2026, the latest employee count at ChemoCentryx is 44.

Is ChemoCentryx a funded company?

ChemoCentryx is a funded company, having raised a total of $80.5M across 5 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Jun 17, 2004.

When was the latest funding round of ChemoCentryx?

ChemoCentryx's latest funding was a $***** Grant (prize money) round on Sep 10, 2019, with participation from 1 investor. Its primary sector is Immunology. In United States, the Immunology sector has seen $4.62B in funding in 2026 to date.

Where does ChemoCentryx rank among its competitors?

ChemoCentryx ranks 28th amongst 440 active competitors, of which 136 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was DBV Technologies, which secured $307M in Apr, 2025.

Who are the top competitors of ChemoCentryx?

ChemoCentryx's top competitors include Biogen, BeiGene and argenx. Among them, DBV Technologies secured the most recent funding round in April, 2025.

ChemoCentryx - 2026 Company Profile, Team, Funding & Competitors

Company Details

ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics for autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease. Has multiple clinical stage products - orphan and rare disease (Ph 2), chronic kidney disease (Ph 2), immuno-oncology (Ph 2), Crohn's disease (Ph 3), other autoimmune/ inflammatory disease (Ph 2).

Website: chemocentryx.com
Registered Address: 835 Industrial Rd. Suite 600 San Carlos, CA 94070

Key Metrics

Founded Year

1997

Location

Mountain View, United States

Stage

Acquired

Total Funding

$80.5M in 5 rounds

Latest Funding Round

Grant (prize money), Sep 10, 2019, $*****

Investors

Jennison & 11 more

Ranked

28^th among 440 active competitors

Employee Count

44 as on Sep 30, 2026

Similar Companies

Biogen & 510 more

Exit Details

Acquired by Amgen (Aug 04, 2022)

View ChemoCentryx's full profile

ChemoCentryx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Chemocentryx, Inc. CIN: 94-3254365 , United States, Active	Nov 07, 1996	-	178 (As on Dec 31, 2021)	-

ChemoCentryx got acquired by Amgen on Aug 04, 2022.

Click here to take a look at ChemoCentryx's acquisition in detail

ChemoCentryx has raised a total funding of $80.5M over 5 rounds. Its first funding round was on Jun 17, 2004. Its latest funding round was a Grant (prize money) round on Sep 10, 2019 for $*****. 1 investor participated in its latest round. ChemoCentryx has 12 institutional investors.

Here is the list of recent funding rounds of ChemoCentryx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 10, 2019	6715286	Grant (prize money)	9047533	7949054	8844293	1151934
Jan 04, 2018	3707559	Post IPO	2343622	1674580	8935394	Hercules Capital
Mar 22, 2007	9158460	Series C	2670886	8272904	1303959	Alta Partners & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of ChemoCentryx's funding rounds and investors

The founders of ChemoCentryx is Thomas Schall.

Here are the details of ChemoCentryx's key team members:

Thomas Schall: Founder & CEO of ChemoCentryx. They are also an angel investor in 1 startup.

View details of ChemoCentryx's Founder profiles and Board Members

ChemoCentryx's employee count trend

ChemoCentryx has 44 employees as of Sep 26. Here is ChemoCentryx's employee count trend over the years:

Uncover ChemoCentryx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ChemoCentryx include Biogen, BeiGene and argenx. Here is the list of Top 10 competitors of ChemoCentryx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	76/100
4th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
5th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	70/100
6th	Ionis 1989, United States, Public	Developer of RNA-targeted medicines for various diseases	-	BB Biotech, Ojp & 1 others	69/100
7th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
8th	Vera Therapeutics 2016, San Francisco (United States), Public	Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases	$117M	Abingworth, Fidelity Investments & 13 others	68/100
9th	Cabaletta Bio 2017, Radnor (United States), Public	Developer of CAAR T cells for B cell-mediated autoimmune diseases	$88.3M	Boxer Capital, Redmile Group & 6 others	68/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	68/100
28th	ChemoCentryx 1997, Mountain View (United States), Acquired	Developing orphan drugs for multiple diseases	$80.5M	Jennison, Vivo Capital & 10 others	64/100